Fatty acids & cardiovascular function
This article was originally published in The Tan Sheet
Executive Summary
Consumption of EPA or DHA may reduce risk of adverse cardiovascular events by increasing systemic arterial compliance (SAC) and lowering total vascular resistance, according to study by Paul Nestel, Baker Medical Research Institute, Melbourne, Australia, et al., in August's American Journal of Clinical Nutrition. Researchers randomized 38 dyslipidemic subjects to receive either 3 g EPA/day, 3 g DHA/day or placebo for seven weeks. Primary endpoints measured were arterial functions, while secondary endpoints consisted of plasma lipid and plasma fatty acid levels. EPA group experienced 36% increase in SAC, which reflects arterial elasticity, while the DHA group saw a 27% increase. Test material was supplied by Hoffmann-La Roche and encapsulated by RP Scherer...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.